About 100 reports

  • 6.3 GILEAD
  • Antiviral
  • World
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • 6.6 OTHER BRANDED DIRECT-ACTING ANTIVIRALS
  • 7.2 REDUCING THE OVERALL COST BURDEN OF DIRECT-ACTING ANTIVIRAL TREATMENT
  • Antiviral
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • BUSINESS SEGMENTATION BY REVENUE
  • GILEAD SCIENCES

GS-##, a therapeutic vaccine, generates T-cell immune responses and acts against cells containing HBV antigens in combination with antiviral therapy.

  • Antiviral
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Increasing Awareness and Accessibility of Next-Generation Direct-Acting Antivirals (DAAs) to Expand the Market
  • summarizes the most recently recommended treatment regimens for HCV infection in
  • Antiviral
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Roche Group
  • Global hepatitis C therapeutics market 2014-2019 ($ millions)
  • Global hepatitis B therapeutics market 2014-2019 ($ millions)

However, choice is limited when it comes to direct-acting antivirals.

  • Antiviral
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • TREATMENT ACCESS
  • 6.6 CHINA

SAFETY AND ANTIVIRAL EFFECT OF MK-##, A NOVEL NNRTI (+FTC/ TDF) in ART-Naive HIV-Infected Patients.

  • Antiviral
  • Asia
  • Japan
  • Gilead Sciences, Inc.
  • ViiV Healthcare Ltd.
  • 2.2 Pipeline Dominated by Direct-Acting Antivirals
  • 2.3 Diverse Range of Host-Targeting and Direct-Acting Antivirals in First-in-Class Pipeline
  • Antiviral
  • World
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

The company has also signed a deal worth $## billion with Moderna for its messenger RNA therapeutics platform in developing new antiviral vaccines and passive immunity therapies.

  • Antiviral
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • ANTIVIRAL DRUGS MARKET IN EMEA
  • MARKET SIZE AND FORECAST
  • Antiviral
  • World
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • GILEAD SCIENCES IN LIVER CIRRHOSIS THERAPEUTICS MARKET SOVALDI
  • To grow a diversified business To simplify the operating model to increase efficiency

The acquisition includes Novira' s antiviral products, including its lead candidate, NVR ##-##.

  • Antiviral
  • Market Size
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.

Applications Covered: - Hepatitis-B antivirals - Hepatitis-C antivirals - Herpes virus - HIV antivirals - Influenza - Other Applications o Pneumonia o Flu End-Users Covered: - Ambulatory Surgical Centers - Clinics - Hospitals Distribution Channels covered: - Hospital Pharmacy Sto

  • Antiviral
  • Asia
  • North America
  • World
  • Forecast
  • Brazil: Fastest Growing Therapy Classes (ATC 3)

BRAZIL IMS Pharmaceutical Pricing & Reimbursement Concise Guide Published March 2017 The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions.

  • Antiviral
  • Therapy
  • Brazil
  • Demand
  • GlaxoSmithKline plc
  • SHARE OF INFECTIOUS DISEASES MARKET IN PHARMACEUTICAL MARKET IN CHINA 2015
  • HIGHLIGHTS

It has direct antiviral activity in tissue culture against RNA viruses.

  • Antiviral
  • China
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

• Where lie the best geographical opportunities for selling those antivirals?

  • Antiviral
  • Hepatitis Treatment
  • Therapy
  • Forecast
  • Market Size

MARKET OVERVIEW.............. ## Antivirals.............. ## Table ##: Antiviral Market by Segment Worldwide (2014) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others ## Infectious Disease Drugs.............. ## Table ##: Infectiou

  • Antiviral
  • Hepatitis
  • Europe
  • Demand
  • Market Shares

Hepatitis C

4546 5000 3864
  • DIRECT-ACTING ANTIVIRALS TARGET KEY VIRAL NON-STRUCTURAL PROTEINS NECESSARY FOR HCV REPLICATION
  • Pivotal studies supporting approvals of Zepatier
  • Antiviral
  • Asia
  • Europe
  • Japan
  • World
  • depicts the treatment algorithm recommended by WHO for the management of chronic hepatitis B infection.
  • Management of Hepatitis B Infection
  • Antiviral
  • Therapy
  • World
  • Gilead Sciences, Inc.
  • Tekmira Pharmaceuticals Corporation
  • 6.3.1 Phase II
  • 3. Hepatitis C - Approved Drugs Sales & Forecast

The study will examine the hypothesis that pretreatment viral testing will identify patients who will respond to antiviral therapy with Telaprevir.

  • Antiviral
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

Interferon and Antiviral ##. ##. ##. ##.

  • Antiviral
  • Hepatitis Treatment
  • Therapy
  • World
  • Market Size

Antivirals?

  • Antiviral
  • Therapy
  • Forecast
  • Market Size

MARKET OVERVIEW.............. ## Antiviral Drugs.............. ## Table ##: Antiviral Market by Segment Worldwide (2014) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others ## Table ##: Hepatitis C Market by Category Worldwide (2015) - Per

  • Antiviral
  • United States
  • World
  • Demand
  • Market Shares
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS

ANTIVIRAL THERAPY SUPPRESSES THE REPLICATION OF HIV INFECTION IN THE BODY.

  • Antiviral
  • China
  • Co. Shanghai Boeringer Ingelheim Pharmaceutical Co., Ltd.
  • Ltd. Beijing Sanjiu Wandong Pharmaceutical Co., Ltd.
  • Ltd. Chengdu Enwei Group Corporation
  • VIRAL INFECTIONS THERAPEUTICS MARKET, GLOBAL, FORECAST ANNUAL REVENUES FOR
  • 4.4.1.4 Failure Rates by Molecular Target

ANTIVIRAL THERAPY TARGETING VIRAL POLYMERASE.

  • Antiviral
  • Therapy
  • World
  • Market Size
  • Gilead Sciences, Inc.
  • 6.2.2 PHASE II CLINICAL TRIALS ANALYSIS
  • 6.4.1 PHASE II CLINICAL TRIALS ANALYSIS

Boceprevir also appears to have some antiviral effect against HCV-## and HCV-## in vivo.

  • Antiviral
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS

Antiviral therapy suppresses the replication of HIV infection in the body.

  • Antiviral
  • China
  • Co. Shanghai Boeringer Ingelheim Pharmaceutical Co., Ltd.
  • Ltd. Beijing Sanjiu Wandong Pharmaceutical Co., Ltd.
  • UNAIDS

HIV

4546 5000 3864
  • ATTACHMENT AND FUSION
  • Current Treatment Options

Antiviral Therapy, ##(##), ##-## < DOI> ##. ##/ imp##< / DOI>.

  • Antiviral
  • Europe
  • United States
  • World
  • Bristol-Myers Squibb Company
  • Trial Results

Recurrent D##BB Antivirals ATC Classification Target Patient Details Age Gender Accept Healthy Volunteer(s) Subject(s) Type Participant Criteria (Inclusion) ## Years and older Both No Glucocorticoid Receptor (GR); Viral DNA Polymerase Participant Criteria (Exclusion) Generally good health

  • Antiviral
  • World
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc
  • Maruho Co., Ltd.
  • 3.4.2 ANTIVIRAL THERAPY
  • RECOMMENDED ANTIVIRAL REGIMENS FOR THE MANAGEMENT OF GH IN IMMUNOCOMPETENT PATIENTS
  • Antiviral
  • Therapy
  • Japan
  • Forecast
  • Genocea Biosciences, Inc.

Antiviral Efficacy of Atripla Compared with Combivir-Efavirenz Combination Therapy ## Table ##: Atripla’s Safety - Adverse Reactions Reported in a ##-Week Clinical Study ## Table ##: Atripla SWOT Analysis, 2014 ## Table ##: Sales Forecasts ($m) for Atripla, 2013-2023 ## Table ##: Product Pr

  • Antiviral
  • Hepatitis Treatment
  • HIV AIDS
  • Therapy
  • United States

Antiviral Efficacy of Atripla Compared with Combivir-Efavirenz Combination Therapy ## Table ##: Atripla’s Safety - Adverse Reactions Reported in a ##-Week Clinical Study ## Table ##: Atripla SWOT Analysis, 2014 ## Table ##: Sales Forecasts ($m) for Atripla, 2013-2023 ## Table ##: Product Pr

  • Antiviral
  • Hepatitis Treatment
  • HIV AIDS
  • Therapy
  • China